Rep. Josh Gottheimer bought Natera (NTRA)
Rep. Josh Gottheimer (D-NJ-5) · $1K–$15K · traded Aug 22, 2025
- Transaction
- Bought
- Amount
- $1K–$15K
- Owner
- Joint
- Traded
- Aug 22, 2025
- Disclosed
- Sep 5, 2025
- Days to disclose
- 14
- Asset type
- Stock
- As filed
- Natera, Inc. - Common Stock
- Industry
- Medical - Diagnostics & Research · Healthcare
Other trades in this filing
- Sep 5, 2025$1K–$15K
$1K–$15K · Traded Aug 21, 2025 · disclosed Sep 5, 2025 · Joint
- Sep 5, 2025$1K–$15K
Sold (partial) International Business Machines IBM
$1K–$15K · Traded Aug 12, 2025 · disclosed Sep 5, 2025 · Joint
- Sep 5, 2025$1K–$15K
$1K–$15K · Traded Aug 12, 2025 · disclosed Sep 5, 2025 · Joint
Committee overlap: Financial ServicesGot $13K from the company’s PAC - Sep 5, 2025$1K–$15K
$1K–$15K · Traded Aug 1, 2025 · disclosed Sep 5, 2025 · Joint
Committee overlap: Financial ServicesGot $13K from the company’s PAC
Recent Congress trades in NTRA
- Oct 15, 2025$1K–$15K
Rep. Josh Gottheimer (D-NJ-5)
$1K–$15K · Traded Sep 22, 2025 · disclosed Oct 15, 2025 · Joint
- Aug 11, 2025$1K–$15K
Rep. Josh Gottheimer (D-NJ-5)
$1K–$15K · Traded Jul 22, 2025 · disclosed Aug 11, 2025 · Joint
- Dec 5, 2024$1K–$15K
Rep. Josh Gottheimer (D-NJ-5)
$1K–$15K · Traded Nov 20, 2024 · disclosed Dec 5, 2024 · Joint
- May 19, 2023$1K–$15K
Rep. Daniel S. Goldman (D-NY-10)
$1K–$15K · Traded Apr 10, 2023 · disclosed May 19, 2023
- Apr 17, 2023$1K–$15K
Rep. Daniel S. Goldman (D-NY-10)
$1K–$15K · Traded Mar 6, 2023 · disclosed Apr 17, 2023
- May 4, 2021$1K–$15K
Sen. Bill Hagerty (R-TN)
$1K–$15K · Traded Apr 20, 2021 · disclosed May 4, 2021
Company context for NTRA
Recent records for the company. These may have been published before or after this trade; compare the dates before drawing a connection.
NTRA: third_quarter 2026 lobbying report
Insurance coverage for laboratory testing.
Public: Oct 19, 2026, 3:02 PM EDTOriginal source ↗NTRA: third_quarter 2026 lobbying report
Health issues. Medicare/Medicaid issues. H.R.5269: RESULTS Act.
Public: Oct 19, 2026, 7:34 AM EDTOriginal source ↗NTRA: third_quarter 2026 lobbying report
Advocacy on importance of FDA's oversight of Laboratory Developed Tests and impact on industry and patients. Advocacy on CMS administrative procedures regarding Date of Service (DOS) for Laboratory testing for patients.
Public: Oct 16, 2026, 4:00 PM EDTOriginal source ↗
From a periodic transaction report filed under the STOCK Act. Amounts are the ranges members report. Nothing here is investment advice.